Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study

Peking University

Status and phase

Completed

Phase 4

Conditions

Acute Schizophrenia Episode

Treatments

Drug: Aripiprazole

Study type

Interventional

Funder types

Other

Identifiers

NCT03289026

320-57-1706-1101-0001

Details and patient eligibility

About

This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics of the population for taking aripiprazole and provide reference for clinical rational drug use.

Full description

The control of acute schizophrenia effectively and rapidly will build up the confidence of patients on treatments. These early effects may influence the long-term compliance and prognosis of patients. Aripiprazole is an important drug in first line treatment of schizophrenia. However, at present in China, the application of aripiprazole in some patients with acute schizophrenia is not appropriate, leading to poor control of the positive symptoms of the acute phase.

The purpose of this single-arm, open-label trial is to study the situation of the use of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to supply important information for optimizing treatment strategies of hospitalized patients characterized by positive symptom.

The hospitalized patients characterized by positive symptom with acute schizophrenia episode were recruited. At the time of enrollment, the demographic, symptomatic and laboratory data was collected. After the completion of the baseline assessment and examination, the patients were given aripiprazole. Clinical evaluation was performed at 1、2、4 and 8 weeks after treatment, including the therapeutic efficacy and adverse drug reactions ,and monitoring of laboratory data.

Enrollment

770 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients meeting International Classification of Diseases (tenth version, ICD-10) criteria for schizophrenia.
acute episode; inpatients
Age from 18-65 years old (inclusion), male or female
PANSS total score at least 70
scoring ≥ 4 on at least two of the following PANSS items: P1 (delusions), P2 (conceptual disorganisation), P3 (hallucinations), P6 (suspiciousness/persecution) ; and PANSS positive score is higher than PANSS negative score
Written informed consent

Exclusion criteria

other serious diseases;
Pregnant or breast feeding women or planning a pregnancy
Patients in a state of drug-induced malignant syndrome or serious extrapyramidal side effect, or with a history of malignant syndrome or serious extrapyramidal side effect;
Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
Allergy to Aripiprazole
History of alcohol or drug abuse or dependence in the past 1-year before screening
mental retardation; bipolar disorder; major depressive disorder;
Currently using one kind of antipsychotic drug at a dose that exceeds the recommended maximum dose for two weeks, but no improvement in core symptoms; or currently using two kinds of antipsychotic drugs, at least one of which reaches or exceeds the recommended maximum dose for two weeks, but no improvement in core symptoms; or currently using three kinds of antipsychotic drugs or more;
Refractory schizophrenia patients who did not respond to treatments of two different type antipsychotics with adequate dose and course
Patients with clinically significant abnormalities on electrocardiogram or laboratory tests
Patients with clinically significant abnormalities on liver function (ALT or AST>2 times of higher limit of normal range)
Patients who had Electroconvulsive Therapy (ECT) in the past 2 months
Participation in a clinical trial of another drug within 4 weeks prior to study entry